Johns Hopkins researchers used mouse ex vivo K14+ breast cancer organoid model to study the effect of tumor exposure to NK cells. teNK cells were found to lose cytotoxicity and to promote metastesis. This effect could be overcome by blockade with anti-TIGIT or anti-KRLG antibodies, both of which are promising immune checkpoints for Cancer therapy.